{"organizations": [], "uuid": "92dac0bf8c1e3292357fe469a1d0e695baafc27f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/business-wire-eagle-pharmaceuticals-inc-to-discuss-first-quarter-2018-financial-results-on-may-10-2018.html", "country": "US", "domain_rank": 767, "title": "Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T00:30:00.000+03:00", "replies_count": 0, "uuid": "92dac0bf8c1e3292357fe469a1d0e695baafc27f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/business-wire-eagle-pharmaceuticals-inc-to-discuss-first-quarter-2018-financial-results-on-may-10-2018.html", "ord_in_thread": 0, "title": "Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018", "locations": [], "entities": {"persons": [{"name": "pete meyers", "sentiment": "none"}, {"name": "scott tarriff", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "woodcliff lake", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "nasd", "sentiment": "negative"}, {"name": "eagle pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "eagle pharmaceuticals, inc", "sentiment": "none"}, {"name": "eagle", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (\"Eagle\" or “the Company”) (Nasdaq: EGRX) today announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.\nScott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:\nDate Thursday, May 10, 2018 Time 8:30 a.m. EDT Toll free (U.S.) 877-876-9176 International 785-424-1667 Webcast (live and replay) www.eagleus.com , under the “Investor Relations” section\nA replay of the conference call will be available for one week after the call's completion by dialing 800-839-3735 (US) or 402-220-2977 (International) and entering conference call ID EGRXQ118. The webcast will be archived for 30 days at the aforementioned URL.\nAbout Eagle Pharmaceuticals, Inc.\nEagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com .\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180501006268/en/\nInvestor Relations for Eagle Pharmaceuticals, Inc:\nLisa M. Wilson, 212-452-2793\nlwilson@insitecony.com\nSource: Eagle Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eagleus.com&esheet=51798902&newsitemid=20180501006268&lan=en-US&anchor=www.eagleus.com&index=1&md5=33e876d380686ad0d67ced89393cfa87", "https://www.businesswire.com/news/home/20180501006268/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eagleus.com&esheet=51798902&newsitemid=20180501006268&lan=en-US&anchor=www.eagleus.com&index=2&md5=fe887b78d3de271091218d26a810e58d"], "published": "2018-05-02T00:30:00.000+03:00", "crawled": "2018-05-02T01:14:45.043+03:00", "highlightTitle": ""}